Stock DNA
Pharmaceuticals & Biotechnology
SEK 498 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.03
-215.40%
5.70
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-48 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-47.5%
0%
-47.5%
6 Months
-43.89%
0%
-43.89%
1 Year
-84.69%
0%
-84.69%
2 Years
-93.41%
0%
-93.41%
3 Years
-98.86%
0%
-98.86%
4 Years
-99.83%
0%
-99.83%
5 Years
-99.89%
0%
-99.89%
Q-linea AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
55.66%
EBIT Growth (5y)
3.42%
EBIT to Interest (avg)
-92.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.43
EV to EBIT
-0.83
EV to EBITDA
-0.92
EV to Capital Employed
1.60
EV to Sales
26.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-191.39%
ROE (Latest)
-139.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1.10
3.70
-70.27%
Operating Profit (PBDIT) excl Other Income
-43.40
-41.10
-5.60%
Interest
0.80
0.60
33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-48.20
-45.20
-6.64%
Operating Profit Margin (Excl OI)
-43,651.00%
-12,297.20%
-3,135.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -70.27% vs 1,750.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -6.64% vs 14.39% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2.40
4.40
-45.45%
Operating Profit (PBDIT) excl Other Income
-197.60
-213.70
7.53%
Interest
0.60
0.90
-33.33%
Exceptional Items
-2.60
2.10
-223.81%
Consolidate Net Profit
-216.90
-229.40
5.45%
Operating Profit Margin (Excl OI)
-91,180.80%
-52,074.10%
-3,910.67%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -45.45% vs -65.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 5.45% vs 14.63% in Dec 2023
About Q-linea AB 
Q-linea AB
Pharmaceuticals & Biotechnology
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
Company Coordinates 
Company Details
Dag Hammarskjolds Vag 52 A , UPPSALA None : 752 37
Registrar Details






